Related Experiment Videos
Activity of coumermycin against clinical isolates of staphylococci
Abstract:
Staphylococci, particularly methicillin-resistant strains of Staphylococcus aureus, are major nosocomial pathogens in large hospitals in eastern Australia. At present vancomycin is the drug of choice for the treatment of life-threatening methicillin-resistant S. aureus infections. A possible alternative drug is coumermycin, a bis-hydroxy coumarin which inhibits DNA gyrase. Coumermycin activity was determined against clinical isolates from the Royal Melbourne Hospital. MICs of 639 staphylococcal isolates were determined by agar dilution. MICs and MBCs of 100 staphylococcal isolates were also determined by microdilution methods. The results showed that coumermycin was bactericidal, with MBCs of less than or equal to 4 micrograms/ml against all isolates tested. The results indicate that coumermycin is a potential alternative to vancomycin in the treatment of severe staphylococcal infections.
Insights
Coumermycin shows bactericidal activity against staphylococcal isolates, including methicillin-resistant Staphylococcus aureus. This antibiotic is a potential alternative to vancomycin for severe infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Staphylococci, especially methicillin-resistant Staphylococcus aureus (MRSA), are significant hospital-acquired pathogens.
- Vancomycin is the current primary treatment for severe MRSA infections.
Purpose of the Study:
- To evaluate coumermycin as a potential alternative to vancomycin for treating staphylococcal infections.
- To determine the antimicrobial activity of coumermycin against clinical isolates.
Main Methods:
- Minimum Inhibitory Concentrations (MICs) of 639 staphylococcal isolates were determined using agar dilution.
- MICs and Minimum Bactericidal Concentrations (MBCs) of 100 staphylococcal isolates were determined via microdilution.
Main Results:
- Coumermycin demonstrated bactericidal activity against all tested staphylococcal isolates.
- MBCs for coumermycin were consistently low, at or below 4 micrograms/ml.
Conclusions:
- Coumermycin exhibits potent bactericidal effects against staphylococci.
- Coumermycin represents a promising alternative therapeutic option for severe staphylococcal infections, including those caused by MRSA.